Advertisement
Research ArticleDrug Discovery and Translational Medicine

Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans

Erica K. Evans, Richland Tester, Sharon Aslanian, Russell Karp, Michael Sheets, Matthew T. Labenski, Steven R. Witowski, Heather Lounsbury, Prasoon Chaturvedi, Hormoz Mazdiyasni, Zhendong Zhu, Mariana Nacht, Martin I. Freed, Russell C. Petter, Alex Dubrovskiy, Juswinder Singh and William F. Westlin
Journal of Pharmacology and Experimental Therapeutics August 2013, 346 (2) 219-228; DOI: https://doi.org/10.1124/jpet.113.203489
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleDrug Discovery and Translational Medicine

Btk Inhibition with the Covalent Inhibitor CC-292

Erica K. Evans, Richland Tester, Sharon Aslanian, Russell Karp, Michael Sheets, Matthew T. Labenski, Steven R. Witowski, Heather Lounsbury, Prasoon Chaturvedi, Hormoz Mazdiyasni, Zhendong Zhu, Mariana Nacht, Martin I. Freed, Russell C. Petter, Alex Dubrovskiy, Juswinder Singh and William F. Westlin
Journal of Pharmacology and Experimental Therapeutics August 1, 2013, 346 (2) 219-228; DOI: https://doi.org/10.1124/jpet.113.203489
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement